Published in Medical Letter on the CDC and FDA, March 2nd, 1998
Nancy Rosenstein, MD, of the National Center for Infectious Diseases at the U.S. Centers for Disease Control and Prevention in Atlanta, Georgia, and colleagues conducted the first study of the vaccine's efficacy when used in a mass vaccination campaign of U.S. civilians aged two- to 29-years-old.
They found the vaccine was 85 percent effective among the entire group and 93 percent effective among those...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA